Keryx Biopharmaceuticals Inc.'s ferric citrate will go to market after approval Friday by the FDA, two days before the drug's Sunday PDUFA date. But the agency rescinded approval of the long-used trade name Zerenex, forcing the company to go back to the drawing board for a name that passes muster.